I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 5 studies | 26% ± 7% | |
| rod bipolar cell | 3 studies | 26% ± 7% | |
| GABAergic neuron | 3 studies | 24% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 5 studies | 26% ± 7% | |
| rod bipolar cell | 3 studies | 26% ± 7% | |
| GABAergic neuron | 3 studies | 24% ± 3% |
Insufficient scRNA-seq data for expression of B3GALT2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 94% | 791.45 | 2483 / 2642 | 97% | 13.76 | 684 / 705 |
| prostate | 78% | 261.73 | 192 / 245 | 70% | 2.52 | 351 / 502 |
| adrenal gland | 40% | 60.34 | 104 / 258 | 64% | 2.99 | 147 / 230 |
| ovary | 93% | 452.07 | 168 / 180 | 10% | 0.34 | 45 / 430 |
| lung | 63% | 170.03 | 365 / 578 | 32% | 1.87 | 366 / 1155 |
| heart | 95% | 1515.24 | 815 / 861 | 0% | 0 | 0 / 0 |
| intestine | 61% | 112.78 | 587 / 966 | 30% | 1.11 | 160 / 527 |
| bladder | 62% | 235.43 | 13 / 21 | 14% | 0.69 | 70 / 504 |
| thymus | 49% | 75.32 | 318 / 653 | 11% | 0.74 | 66 / 605 |
| stomach | 32% | 62.40 | 116 / 359 | 27% | 1.00 | 77 / 286 |
| kidney | 49% | 71.89 | 44 / 89 | 9% | 0.24 | 82 / 901 |
| pancreas | 3% | 3.42 | 9 / 328 | 51% | 2.26 | 90 / 178 |
| skin | 25% | 280.01 | 452 / 1809 | 22% | 1.21 | 105 / 472 |
| esophagus | 19% | 32.08 | 279 / 1445 | 27% | 0.79 | 50 / 183 |
| liver | 4% | 3.59 | 8 / 226 | 13% | 1.99 | 51 / 406 |
| spleen | 15% | 19.60 | 36 / 241 | 0% | 0 | 0 / 0 |
| adipose | 14% | 18.85 | 172 / 1204 | 0% | 0 | 0 / 0 |
| breast | 6% | 7.69 | 29 / 459 | 5% | 0.29 | 60 / 1118 |
| tonsil | 0% | 0 | 0 / 0 | 11% | 0.15 | 5 / 45 |
| blood vessel | 11% | 20.73 | 145 / 1335 | 0% | 0 | 0 / 0 |
| uterus | 1% | 1.62 | 2 / 170 | 9% | 0.64 | 40 / 459 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.13 | 4 / 80 |
| peripheral blood | 1% | 1.68 | 13 / 929 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.17 | 1 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0009312 | Biological process | oligosaccharide biosynthetic process |
| GO_0006493 | Biological process | protein O-linked glycosylation |
| GO_0006682 | Biological process | galactosylceramide biosynthetic process |
| GO_0006486 | Biological process | protein glycosylation |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0008499 | Molecular function | UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity |
| GO_0047275 | Molecular function | glucosaminylgalactosylglucosylceramide beta-galactosyltransferase activity |
| Gene name | B3GALT2 |
| Protein name | Beta-1,3-galactosyltransferase 2 (Beta-1,3-GalTase 2) (Beta3Gal-T2) (Beta3GalT2) (EC 2.4.1.86) (UDP-galactose:2-acetamido-2-deoxy-D-glucose 3beta-galactosyltransferase 2) |
| Synonyms | |
| Description | FUNCTION: Beta-1,3-galactosyltransferase that transfers galactose from UDP-galactose to substrates with a terminal beta-N-acetylglucosamine (beta-GlcNAc) residue. Can also utilize substrates with a terminal galactose residue, albeit with lower efficiency. Involved in the biosynthesis of the carbohydrate moieties of glycolipids and glycoproteins. Inactive towards substrates with terminal alpha-N-acetylglucosamine (alpha-GlcNAc) or alpha-N-acetylgalactosamine (alpha-GalNAc) residues. . |
| Accessions | O43825 ENST00000367434.5 |
